Personalis, Inc. develops, markets, and sells advanced cancer genomic testing services. The company provides tumor-informed liquid biopsy tests for detecting minimal residual disease (MRD) and monitoring cancer recurrence, as well as comprehensive tumor profiling for therapy selection. Key products include NeXT Personal Dx, NeXT Dx, NeXT Personal, and ImmunoID NeXT. Personalis also offers whole exome sequencing (WES) and whole genome sequencing (WGS) services for diagnostic companies and population sequencing initiatives. Its customers include global pharmaceutical and biopharmaceutical companies, diagnostics firms, academic institutions, and cancer patients. The company serves markets in the United States, Europe, and Asia-Pacific. Personalis collaborates with Tempus to co-commercialize its MRD testing services and works with various academic and research institutions to build clinical evidence for its assays. Founded in 2011, the company operates a CLIA-certified and CAP-accredited laboratory.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Diagnostics & Research Homepage personalis.com
Sector Healthcare IR page investors.personalis.com
Tags
cancer genomics, liquid biopsy, minimal residual disease, next-generation sequencing, companion diagnostics, biomarker discovery, tumor profiling, precision oncology, NeXT Personal Dx, NeXT Dx, NeXT Personal, ImmunoID NeXT, Real-Time Variant Tracker, WES, WGS
Press page —

Metrics

Valuation  
Market cap $ 1.72B
Market cap (USD) $ 1.72B
P/E -13.56
PEG —
P/BV 8.09
P/S 21.29
P/OCF -17.63
P/FCF -15.97
Dividend yield —
Turnover / mcap —
Returns  
ROE -35.0%
ROI -31.0%
ROIC -25.2%
Profit margin -116.7%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 83
Quality score -72.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Revenue 69.648M 84.614M 73.481M 65.047M 85.494M 78.648M 65.207M 37.774M
Net profit -81.27M -81.284M -108.296M -113.315M -65.226M -41.28M -25.084M -19.886M
Free cash flow -79.45M -46.753M -67.169M -120.129M -81.911M -45.899M -26.451M -2.28M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Share price 7.96 5.78 2.1 1.98 14.27 36.61 10.9 —
Price performance 12m 0.38 1.75 0.06 -0.86 -0.61 2.36 — —

Filed figures

Figure Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — 4.46M 3.3M 6.35M 18.5M 16.6M 17.7M 8.14M 16.2M
↳ YoY growth -26.0% +92.4% +190.9% -9.9% +6.5% -54.1% +99.1%
↳ 5y CAGR +31.8% +19.8% +20.6%
Borrowings, current (USD) — 9.99M — — — — — — —
Lease liabilities (USD) — — 2M 11M 56.5M 46.4M 46.1M 42.6M 42M
Cash and deposits (USD) 22.6M 19.7M 55M 68.5M 106M 89.1M 57M 91.4M 124M
Right-of-use assets (USD) — — 1.85M 10.3M 53.8M 26.5M 17.9M 16.5M 15.1M
Net debt (borrowings + leases - cash) (USD) — -9.75M — — — — — — —
Cash flow detail
Operating cash flow (USD) 290,000 5.57M -18.1M -42.7M -70.8M -70.2M -56.3M -45.2M -74.9M
Purchases of property, plant and equipment (USD) -5.16M -7.85M -8.38M -3.25M -11.1M -49.9M -10.9M -1.6M -4.5M
Change in receivables (cash effect) (USD) -1.2M -2.52M 1.07M -3.05M -12.1M 1.83M -1.09M 9.59M -8.06M
Change in payables (cash effect) (USD) 2.64M 2.16M 1.4M 751,000 -1.46M 3.09M 5.18M -8.92M 4.55M
Interest paid (cash effect) (USD) -321,000 -698,000 -1.26M — — — — — —
Income taxes paid (cash effect) (USD) -5,000 -7,000 -6,000 -35,000 -39,000 -47,000 -64,000 -38,000 -23,000
Share-based compensation (USD) 753,000 1.32M 4.86M 8.24M 14.4M 19.4M 14.1M 10.7M 9.43M
Operating cash flow before change in receivables (USD) 1.49M 8.09M -19.1M -39.6M -58.7M -72.1M -55.2M -54.7M -66.9M
Free cash flow (OCF - PPE - intangibles) (USD) -4.87M -2.28M -26.5M -45.9M -81.9M -120M -67.2M -46.8M -79.5M
Income detail
Research and development expense (USD) 9.92M 14.3M 22.4M 28.6M 49.3M 64.9M 64.8M 48.9M 50.3M
↳ 5y CAGR +45.6% +35.3% +16.9% +12.0%
Total comprehensive income (USD) -23.6M -19.9M -25.1M -41.3M -65.4M -114M -108M -81.1M -81.1M
Comprehensive income to owners (USD) -23.6M -19.9M -25.1M -41.3M -65.4M -114M -108M -81.1M -81.1M
Provision for credit losses (USD) 0.00 0.00 — 0.00 0.00 — — — —
Credit cost ratio (credit losses / average receivables) (%) — — — 0.0% 0.0% — — — —
Reported Mar 25, 2020 Mar 25, 2020 Mar 25, 2020 Feb 25, 2021 Feb 24, 2022 Feb 23, 2023 Feb 28, 2024 Feb 27, 2025 Feb 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Personalis Reports Third Quarter Results Bull 5 Bear 0 Results

November 4, 2026

PDF Version

Reports Q3 clinical test volume of 13,157, clinical revenue of $4.4 million and overall revenue of $25.6 million

FREMONT, Calif.--(BUSINESS WIRE)--Nov. 4, 2026-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the third quarter ended September 30, 2026.

Recent Strategic and Operational Highlights

  • Launched NeXT Personal®**Real-Time Variant Tracker™:**Commercially launched optional Real-Time Variant Tracker supplemental results in the NeXT Personal molecular residual disease (MRD) test report, which identify clinically relevant resistance and therapeutically targetable variants over time, during NeXT Personal testing.

  • Reported pre-interim results from prospective Triple Negative Breast Cancer (TNBC) B-STRONGER-1 study: Personalis’ study is a multi-site, prospective study evaluating ctDNA dynamics in stage I-III TNBC patients receiving neoadjuvant therapy (NAT). Results showed high sensitivity, achieving a 96% ctDNA detection rate at baseline with 83.3% of positive detections at T1 in the ultrasensitive range below 100 PPM. Also, the results showed an 82% ctDNA clearance rate following two cycles of NAT.

  • Demonstrated the value of ultrasensitive ctDNA for predicting early immunotherapy response: A study conducted with The University of California, San Diego (UCSD) for 55 patients across 8 metastatic cancer types showed that an ultrasensitive assay may provide resolution in cases of heterogeneous response to stratify patients with radiographically stable disease into distinct risk groups, and dynamic ctDNA monitoring during immunotherapy provides lead time for identifying patients at high risk of progression.

Third Quarter 2026 Financial Results Compared with Third Quarter 2025

  • Quarterly Revenue: Total revenue of $25.6 million compared with $14.5 million, primarily driven by growth in clinical test revenue, as well as core revenue from increased population sequencing and higher pharma testing services.

  • Clinical Revenue: Clinical test revenue of $4.4 million compared with $0.4 million, resulting from the increase in test volume and also a full quarter of Medicare covered IO test volume, in addition to revenue from breast and lung cancer covered tests; delivered 13,157 clinical tests compared with 4,388.

  • Core Revenue Streams: Revenue from pharma testing services and all other customers totaled $17.2 million compared with $13.2 million. Revenue from population sequencing (the VA MVP) totaled $4.0 million compared with $0.2 million.

  • Cash Position: Ended the quarter with approximately $190.6 million in cash, cash equivalents, and short-term investments.

CEO Commentary

“These results reflect the strength of our team’s execution and commitment to helping transform the active management of cancer through more informed care,” said Chris Hall, Chief Executive Officer of Personalis. “Combining with Tempus gives us the scale, complementary capabilities and resources to accelerate innovation and deliver even greater value to patients, clinicians, and biopharma partners.”

Full Year 2026 Outlook

As a result of the announcement on July 20, 2026, that Personalis and Tempus AI, Inc. have entered into an Agreement and Plan of Merger, Personalis will no longer provide financial guidance or conduct a quarterly earnings conference call.

About Personalis, Inc.

At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable the selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on LinkedIn and X (Twitter).

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and can generally be identified by terms such as “anticipate,” “estimate,” “expect,” “if,” “may,” “future,” “will” or similar expressions. These statements include statements relating to: the attributes, advantages, capabilities, sensitivity, availability and clinical relevance of the NeXT Personal test and the potential impact or expected benefits of the Personalis’ published data and presentations and statements regarding the proposed transaction between Personalis and Tempus AI, Inc. (Tempus) and the benefits of such transaction. Such forward-looking statements involve known and unknown risks and uncertainties and other factors that may cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements, including the risks, uncertainties and other factors that relate to the pending acquisition by Tempus, including the occurrence of any event, change or other circumstances that could give rise to the termination of the Agreement and Plan of Merger (the Agreement), the possibility that Personalis shareholders may not adopt the Agreement, the risk that the parties may not be able to satisfy the conditions to the proposed transaction in a timely manner or at all, risks related to disruption of management time from ongoing business operations due to the proposed transaction, the risk that any announcements relating to the proposed transaction could have adverse effects on the market price of Personalis’ common stock or Tempus’ common stock, the risk of any litigation relating to the proposed transaction, the risk that the proposed transaction and its announcement could have an adverse effect on the ability of Personalis and/or Tempus to retain and hire key personnel; the timing and pace of new orders from customers, including from ModernaTX, Inc., Merck Sharp & Dohme LLC and other biopharma customers, and the VA MVP; the success of Personalis’ and Tempus’ respective sales and marketing efforts; the timing of tissue, blood, and other specimen sample receipts from customers, which can materially impact revenue quarter-over-quarter and year-over-year; Personalis’ ability to demonstrate attributes, advantages or clinical validity of the NeXT platform; future clinical data differing from the clinical data previously presented or expected results; Personalis’ ability to obtain Medicare coverage and reimbursement in additional indications and the timing thereof; the impact of competition and macroeconomic factors on Personalis’ business; the partnering and/or collaboration arrangements that Personalis has entered into or may enter into in the future may not be successful, or may terminate, which could adversely impact Personalis’ business or affect its ability to develop and commercialize its services and products; having a limited number of suppliers; and customer concentration. These and other potential risks and uncertainties that could cause actual results to differ materially from the results predicted in these forward-looking statements are described under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Personalis’ Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the Securities and Exchange Commission (SEC) on August 4, 2026 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, to be filed with the SEC on November 4, 2026. All information provided in this release is as of the date of this press release, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. Personalis undertakes no duty to update this information unless required by law.

| PERSONALIS, INC. |

| CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) |

| (In thousands, except share and per share data) |

| | | | | | | |

| | | Three Months Ended September 30, | | | Nine Months Ended September 30, | |

| | | 2026 | | | 2025 | | | 2026 | | | 2025 | |

| Consolidated Statements of Operations: | | | | | | | | | |

| Revenue (1) | | $ | 25,596 | | | $ | 14,495 | | | $ | 63,425 | | | $ | 52,303 | |

| Costs and expenses | | | | | | | | | | | | |

| Cost of revenue | | | 19,026 | | | | 12,581 | | | | 51,831 | | | | 38,426 | |

| Research and development | | | 16,074 | | | | 12,171 | | | | 46,949 | | | | 37,192 | |

| Selling, general and administrative (2) | | | 26,014 | | | | 13,034 | | | | 65,915 | | | | 39,476 | |

| Total costs and expenses | | | 61,114 | | | | 37,786 | | | | 164,695 | | | | 115,094 | |

| Loss from operations | | | (35,518 | ) | | | (23,291 | ) | | | (101,270 | ) | | | (62,791 | ) |

| Interest income | | | 1,760 | | | | 1,680 | | | | 5,898 | | | | 5,585 | |

| Interest expense | | | (36 | ) | | | (64 | ) | | | (120 | ) | | | (140 | ) |

| Other income (expense), net | | | (4 | ) | | | 26 | | | | — | | | | (100 | ) |

| Loss before income taxes | | | (33,798 | ) | | | (21,649 | ) | | | (95,492 | ) | | | (57,446 | ) |

| Provision for income taxes | | | 3 | | | | 3 | | | | 24 | | | | 12 | |

| Net loss | | $ | (33,801 | ) | | $ | (21,652 | ) | | $ | (95,516 | ) | | $ | (57,458 | ) |

| Net loss per share, basic and diluted | | $ | (0.32 | ) | | $ | (0.24 | ) | | $ | (0.90 | ) | | $ | (0.65 | ) |

| Weighted-average shares outstanding, basic and diluted | | | 107,206,827 | | | | 88,699,131 | | | | 105,607,799 | | | | 88,226,838 | |

| | |

| (1) Includes related party revenue of $5.9 million and $1.1 million for the three months ended September 30, 2026 and 2025, respectively, and $17.4 million and $3.5 million for the nine months ended September 30, 2026 and 2025, respectively. |

| (2) Includes related party sales and marketing expenses of $4.8 million and $1.2 million for the three months ended September 30, 2026 and 2025, respectively, and $11.5 million and $2.7 million for the nine months ended September 30, 2026 and 2025, respectively. |

| PERSONALIS, INC. |

| SUPPLEMENTAL REVENUE INFORMATION (Unaudited) |

| (In thousands) |

| | | | | | | |

| | | Three Months Ended September 30, | | | Nine Months Ended September 30, | |

| | | 2026 | | 2025 | | 2026 | | 2025 |

| Pharma testing services (1) | | $ | 17,114 | | | $ | 13,137 | | | $ | 44,627 | | | $ | 37,754 | |

| Enterprise sales | | | 8 | | | | 650 | | | | 401 | | | | 5,430 | |

| Population sequencing | | | 4,067 | | | | 234 | | | | 9,567 | | | | 7,755 | |

| Clinical diagnostic | | | 4,374 | | | | 384 | | | | 8,346 | | | | 1,161 | |

| Other | | | 33 | | | | 90 | | | | 484 | | | | 203 | |

| Total revenue | | $ | 25,596 | | | $ | 14,495 | | | $ | 63,425 | | | $ | 52,303 | |

| | |

| (1) Includes related party revenue of $5.9 million and $1.1 million for the three months ended September 30, 2026 and 2025, respectively, and $17.4 million and $3.5 million for the nine months ended September 30, 2026 and 2025, respectively. |

| PERSONALIS, INC. |

| CONSOLIDATED BALANCE SHEETS (Unaudited) |

| (In thousands, except share and par value data) |

| | | | | | | |

| | | September 30, 2026 | | | December 31, 2025 | |

| Assets | | | | | | | | |

| Current assets | | | | | | | | |

| Cash and cash equivalents | | $ | 98,271 | | | $ | 124,245 | |

| Short-term investments | | | 92,331 | | | | 115,708 | |

| Accounts receivable, net (1) | | | 18,035 | | | | 16,203 | |

| Inventory and other deferred costs | | | 7,384 | | | | 6,144 | |

| Prepaid expenses and other current assets | | | 7,029 | | | | 5,651 | |

| Total current assets | | | 223,050 | | | | 267,951 | |

| Property and equipment, net | | | 50,316 | | | | 44,815 | |

| Operating lease right-of-use assets | | | 14,763 | | | | 15,118 | |

| Other long-term assets | | | 3,471 | | | | 6,280 | |

| Total assets | | $ | 291,600 | | | $ | 334,164 | |

| Liabilities and Stockholders’ Equity | | | | | | |

| Current liabilities | | | | | | |

| Accounts payable (2) | | $ | 14,488 | | | $ | 12,989 | |

| Accrued and other current liabilities (2) | | | 33,139 | | | | 25,079 | |

| Contract liabilities | | | 1,647 | | | | 1,562 | |

| Total current liabilities | | | 49,274 | | | | 39,630 | |

| Long-term operating lease liabilities | | | 29,296 | | | | 31,866 | |

| Other long-term liabilities | | | 360 | | | | 1,483 | |

| Total liabilities | | | 78,930 | | | | 72,979 | |

| Commitments and contingencies | | | | | | |

| Stockholders’ equity | | | | | | |

| Preferred stock, $0.0001 par value — 10,000,000 shares authorized; none issued | | | — | | | | — | |

| Common stock, $0.0001 par value — 200,000,000 shares authorized; 108,378,087 and 102,475,891 shares issued and outstanding, respectively | | | 10 | | | | 10 | |

| Additional paid-in capital | | | 939,603 | | | | 892,331 | |

| Accumulated other comprehensive income (loss) | | | (167 | ) | | | 104 | |

| Accumulated deficit | | | (726,776 | ) | | | (631,260 | ) |

| Total stockholders’ equity | | | 212,670 | | | | 261,185 | |

| Total liabilities and stockholders’ equity | | $ | 291,600 | | | $ | 334,164 | |

| | |

| (1) Includes related party accounts receivable of $4.2 million and $2.5 million as of September 30, 2026 and December 31, 2025, respectively. |

| (2) Includes related party liabilities of $5.0 million and $5.7 million as of September 30, 2026 and December 31, 2025, respectively. |

View source version on businesswire.com: https://www.businesswire.com/news/home/20261104890700/en/

Investor Relations: Caroline Corner [email protected] 646-277-1279

Media: [email protected]

Source: Personalis, Inc.

Logo of Personalis, featuring a stylized green and black circular icon with abstract human figures, followed by the word Personalis in black text.

©2026 Personalis, Inc. All rights reserved. All trademarks are the property of Personalis, Inc. or their respective owners. All products described here are for Research Use Only and not for use in diagnostic procedures (except as specifically noted).

  • Social Link

  • Social Link

  • Social Link

October 21, 2026

PDF Version

Late-breaking oral presentation highlights the role of ultrasensitive ctDNA in drug development; first data from prospective B-STRONGER-1 study in early-stage triple-negative breast cancer

FREMONT, Calif.--(BUSINESS WIRE)--Oct. 21, 2026-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that two oral presentations and two poster presentations featuring its NeXT Personal ultrasensitive circulating tumor DNA (ctDNA) test will be presented at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27 in Madrid, Spain. Highlights include a late-breaking oral presentation of NeXT Personal data for the C-POST Phase 3 study in cutaneous squamous cell carcinoma, as well as a Rapid Oral presentation from B-STRONGER-1, a prospective, multicenter study evaluating NeXT Personal for detecting molecular residual disease in patients with early-stage triple-negative breast cancer receiving neoadjuvant therapy.

“B-STRONGER-1 builds on our earlier work in triple-negative breast cancer demonstrating the use of ultrasensitive MRD testing for monitoring neoadjuvant therapy response,” said Richard Chen, MD, President and Chief Medical Officer of Personalis. “We are also excited to see NeXT Personal data presented from biopharma in new indications like cutaneous squamous cell carcinoma as we continue to expand evidence around NeXT Personal for a broad range of solid tumors.”

Presentation Schedule

Late-Breaking Oral Presentation

  • Title: C-POST phase 3 trial of adjuvant (adj) cemiplimab (cemi) vs placebo (pbo) for high-risk cutaneous squamous cell carcinoma (CSCC): Updated overall survival (OS) and outcomes from circulating tumour DNA (ctDNA) analyses

  • Presenter: Danny Rischin, M.D.; Peter MacCallum Cancer Centre

  • Abstract: LBA59 | Session: Rapid Oral - Melanoma and Other Skin Tumours

  • Time: Sun, 10/25/2026, 10:42 - 10:47 CET

  • Location: Granada Auditorium - Hall 4

Rapid Oral Presentation – B-STRONGER-1

  • Title: Ultrasensitive monitoring of early ctDNA dynamics during neoadjuvant treatment in early-stage triple-negative breast cancer: Pre-interim results from the B-STRONGER-I study

  • Presenter: Carlos Barcenas, M.D.; The University of Texas MD Anderson Cancer Center

  • Abstract: 540RO | Session: Rapid Oral - Breast Cancer, Early Stage

  • Time: Fri, 10/23/2026, 16:42 - 16:47 CEST

  • Location: Alicante Auditorium - Hall 6

Poster Presentations

  • **Title:**Ultrasensitive ctDNA kinetics predict early immunotherapy response and complement radiographic assessment in advanced cancer. (UC San Diego). Abstract # 4280P | Session: Translational Research and Biomarkers | **Time:**Fri, 10/23/2026, 15:15 - 16:00 CEST | **Location:**Poster Area - Hall 5

  • Title: Circulating tumour DNA (ctDNA), cancer antigen 125 (CA125) and human epididymis protein 4 (HE4) associate with survival outcomes in patients with platinum- resistant ovarian cancer (PROC) treated with ubamatamab (uba). (Yonsei University Health System). Abstract # 1957P | Session: Investigational Immunotherapy | Time: Sat, 10/24/2026, 12:00 - 12:45 CEST | **Location:**Poster Area - Hall 5

About Personalis, Inc.

At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on LinkedIn and X (Twitter).

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and can generally be identified by terms such as "believe," "expect," "if," "may," "will" or similar expressions. These statements include those relating to: the clinical performance, clinical utility or clinical impact of NeXT Personal, including its ability to detect molecular residual disease in early-stage triple-negative breast cancer or to provide a clearer assessment of treatment response and residual disease; the results or significance of the studies presented; and the role of ultrasensitive ctDNA testing in drug development and clinical research. Such forward-looking statements involve known and unknown risks and uncertainties and other factors that may cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements, including the risks, uncertainties and other factors that relate to Personalis' ability to demonstrate attributes, advantages or clinical validity or utility of the NeXT Personal test, including the NeXT Personal MRD assay remaining unique in its ability to detect traces of cancer in the ultrasensitive range; future clinical data differing from the clinical data previously presented or expected results; the rate of adoption and use of the NeXT Personal test; changes in health care policy, which could increase Personalis' costs, decrease Personalis' revenue, and impact sales of and reimbursement for Personalis' tests; Personalis' ability to obtain Medicare coverage and reimbursement in additional indications and the timing thereof; the impact of competition and macroeconomic factors on Personalis' business; the partnering and/or collaboration arrangements that Personalis has entered into or may enter into in the future may not be successful, or may terminate, which could adversely impact Personalis' business or affect its ability to develop and commercialize its services and products; having a limited number of suppliers; and customer concentration. These and other potential risks and uncertainties that could cause actual results to differ materially from the results predicted in these forward-looking statements are described under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Personalis' Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. All information provided in this release is as of the date of this press release, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. Personalis undertakes no duty to update this information unless required by law.

Not affiliated with or endorsed by ESMO.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261019479647/en/

Investors: Caroline Corner [email protected] 415-202-5678

Media Contact: [email protected]

Source: Personalis, Inc.

Logo of Personalis, featuring a stylized green and black circular icon with abstract human figures, followed by the word Personalis in black text.

©2026 Personalis, Inc. All rights reserved. All trademarks are the property of Personalis, Inc. or their respective owners. All products described here are for Research Use Only and not for use in diagnostic procedures (except as specifically noted).

  • Social Link

  • Social Link

  • Social Link

October 20, 2026

PDF Version

Real-Time Variant Tracker™ supplemental results track resistance and therapeutically targetable variants as cancer biology evolves.

FREMONT, Calif.--(BUSINESS WIRE)--Oct. 20, 2026-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the commercial launch of optional Real-Time Variant Tracker supplemental results in the NeXT Personal molecular residual disease (MRD) test report. These results identify clinically relevant resistance and therapeutically targetable variants over time, during NeXT Personal testing. Real-Time Variant Tracker includes variants with established clinical significance, including associations with FDA-approved therapies and recommendations in National Comprehensive Cancer Network® (NCCN®) guidelines.

“At Personalis, we have continued to push the boundaries of what’s possible with MRD testing, beginning with ultrasensitive detection and now with variant tracking,” said Richard Chen, MD, President & Chief Medical Officer of Personalis. “Real-Time Variant Tracker was developed in recognition that clinically informative variants, including resistance mutations, can emerge during MRD monitoring.”

“The ultrasensitivity of NeXT Personal allows us to detect very low levels of ctDNA, which can be particularly important when we’re monitoring patients whose disease may be difficult to assess through conventional measures alone,” said Dr. Leo Shunyakov, M.D., medical oncologist and hematologist at Central Care Cancer Center. “I see opportunities for highly sensitive ctDNA testing in settings including historically challenging tumor types such as earlier-stage breast and lung cancers. And as we follow patients over time, we’re not only asking whether disease is present, but also how the biology of the cancer may be changing. Real-Time Variant Tracker follows those changes over the course of NeXT Personal testing.”

Personalis first introduced Real-Time Variant Tracker through an Early Access Program in January 2026, giving select clinical and academic users an opportunity to incorporate the supplemental results in real-world clinical practice.

Availability

With today’s launch, Real-Time Variant Tracker becomes commercially available as an optional supplemental result in the NeXT Personal test report beginning October 20, 2026.

About Personalis, Inc.

At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect MRD and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on LinkedIn and X (Twitter).

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts, including statements relating to: the attributes, advantages, capabilities, sensitivity, availability and clinical relevance of Personalis’ assays and products including the NeXT Personal test and optional Real-Time Variant Tracker supplemental results, the ability for Real-Time Variant Tracker to identify clinically relevant resistance and therapeutically targetable variants and inform new opportunities to optimize patient management, adoption of Real-Time Variant Tracker by physicians and Personalis’ biopharma partners, and the success of Personalis’ continued innovation in the MRD space. Such forward-looking statements involve known and unknown risks and uncertainties and other factors that may cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements, including the risks, uncertainties and other factors that relate to Personalis’ ability to demonstrate attributes, advantages or clinical validity of the NeXT Personal test and Real-Time Variant Tracker supplemental results, the NeXT Personal MRD assay remaining unique in its ability to detect traces of cancer in the ultrasensitive range and its ability to monitor mutations; future clinical data differing from the clinical data previously presented or expected results; the rate of adoption and use of the NeXT Personal test and Real-Time Variant Tracker; changes in health care policy, which could increase Personalis’ costs, decrease Personalis’ revenue, and impact sales of and reimbursement for Personalis’ tests; the impact of competition and macroeconomic factors on Personalis’ business; the partnering and/or collaboration arrangements that Personalis has entered into or may enter into in the future may not be successful, or may terminate, which could adversely impact Personalis’ business or affect its ability to develop and commercialize its services and products; having a limited number of suppliers; and customer concentration. These and other potential risks and uncertainties that could cause actual results to differ materially from the results predicted in these forward-looking statements are described under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Personalis’ Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. All information provided in this release is as of the date of this press release, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. Personalis undertakes no duty to update this information unless required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261020218501/en/

Investor Relations: Caroline Corner [email protected] 646-277-1279

Media: [email protected]

Source: Personalis, Inc.

Logo of Personalis, featuring a stylized green and black circular icon with abstract human figures, followed by the word Personalis in black text.

©2026 Personalis, Inc. All rights reserved. All trademarks are the property of Personalis, Inc. or their respective owners. All products described here are for Research Use Only and not for use in diagnostic procedures (except as specifically noted).

  • Social Link

  • Social Link

  • Social Link

Prompts

Personalis, Inc. (ticker PSNL), listed in United States.

ETFs Holding Personalis, Inc.

ETF Weight in ETF Shares Market value As of
TMED 0.12% 1,990 $ 26.666K Jun 30, 2026
DFAS 0.02% 458,476 $ 7.271M Nov 12, 2026
MSSM 0.01% 4,350 $ 72.993K Aug 31, 2026
DFSU 0.00% 4,282 $ 67.913K Nov 12, 2026
DFAC 0.00% 152,497 $ 2.419M Nov 12, 2026
DFAU 0.00% 18,648 $ 295.757K Nov 12, 2026
DCOR 0.00% 57,366 $ 909.825K Nov 12, 2026
DFUS 0.00% 16,101 $ 255.362K Nov 12, 2026
DXUV 0.00% 384 $ 6,090.24 Nov 12, 2026
AVUS 0.00% 632 $ 9,353.60 Nov 16, 2026